VANCOUVER, British Columbia, June 07, 2022 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of marijuana breathalyzer devices for law enforcement and the workplace reports that it will attending and presenting its research: Correlation of Breath and Blood Cannabis Levels Using Custom-Made Breath Sample Collection and Analysis Methods at Breath Summit 2022 hosted by the International Association of Breath Research (IABR) in mid-June 2022. The IABR Breath Summit is one the premier events held globally in relation to breath research. The conference is focused on the latest breakthroughs and emerging topics in breath chemical analysis, sensor instrumentation and biomarker detection and identification strategies. The conference attracts worldwide attendees from multidisciplinary industry and academic groups.
Cannabix will present its technical expertise in breath aerosol analysis and recent breath testing benchmarks with its FAIMS and THC Breath Analyzer technologies for detection of ∆9-tetrahydrocannabinol (“THC”). In addition, Cannabix will present its results from THC analytes captured in human breath performed by an independent experimental study. The study showed excellent correlation between breath samples collected and analyzed with Cannabix hardware and blood plasma levels of THC (see news release dated May 9, 2022). The Company’s handheld Breath Collection Unit and newly developed laboratory “MS Breath Sampler” were used together to provide a new ground-breaking method for portable drug detection that complements gold-standard mass spectrometry. The Company has developed a unique breath analysis system, capable of sampling breath for low volatility analytes, like THC, and can be completed within seconds, with no sample preparation needed.
The Company is in discussions with a range of law enforcement groups who are seeking to test this hardware and will provide further updates as they become available.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana breathalyzer technologies for law enforcement and the workplace. Cannabix is working to develop drug-screening devices that will detect THC – the psychoactive component of marijuana that causes impairment using breath samples. Breath testing for THC would allow employers and law enforcement to identify recent marijuana use that better aligns with impairment. Cannabix devices are in the advanced prototype and pre-clinical testing stage.
We seek Safe Harbor.
On behalf of the Board of Directors
Cannabix Technologies Inc.
For further information, contact the Company at firstname.lastname@example.org
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (iv) the ability of the Company to develop and market its future product; and (v) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that its development of marijuana breathalyzer technology will provide any benefit to the Company, and no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials. There is no assurance that existing “patent pending” technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.